Key result
Oral relugolix requires weighing compliance, cost, and patient preference against injectable ADT formulations.
Why the study?
A balanced discussion is required to understand the clinical settings where oral relugolix has benefits over long-acting injectable ADT formulations, considering patient preference, compliance, financial toxicity, and pharmacologic characteristics.
In what clinical settings does oral relugolix have benefit over long-acting injectable formulations of ADT for prostate cancer?
In what clinical settings does oral relugolix have benefit over long-acting injectable formulations of ADT for prostate cancer?
This review discusses the clinical settings where oral relugolix offers advantages over injectable ADT for prostate cancer, considering patient preference, compliance, and financial toxicity.
Answers are grounded in this paper and cite their sources.
Patient-specific factors should guide oral relugolix use in prostate cancer; leaves open comparative advantages over injectables.
Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and perhaps most importantly, pharmacologic characteristics must be considered.
No takes yet. Share an insight, caveat, or question.
Cordes et al. (2023) conducted a review in Prostate cancer. Relugolix vs. Long-acting injectable formulations of ADT was evaluated. Relugolix, an oral androgen deprivation therapy for prostate cancer, requires consideration of patient preference, compliance, and financial toxicity compared to injectable formulations.
Synapse has enriched 10 related papers. Consider them for comparative context: